论文部分内容阅读
目的探讨左乙拉西坦对癫患儿血清超敏C反应蛋白(hs-CRP)、S100B蛋白的影响。方法 60例癫患儿随机分为对照组30例,观察组30例。对照组采用丙戊酸钠治疗,观察组采用左乙拉西坦治疗。于治疗前和治疗6个月测定患儿血清hs-CRP和S100B蛋白的表达。结果 2组临床疗效比较,观察组控制9例,显效18例,无效3例,总有效率为90.0%;对照组控制5例,显效17例,无效8例,总有效率为73.3%,2组比较差异有统计学意义(P<0.05)。观察组治疗后患儿血清hs-CRP和S100B蛋白分别为(1.38±0.61)mg.L-1和(0.516±0.204)μg.L-1,对照组治疗后分别为(2.96±1.42)mg.L-1和(0.674±0.216)μg.L-1,2组均较治疗前下降,且观察组降低程度较对照组更明显(P<0.05)。结论左乙拉西坦可通过降低hs-CRP和S100B蛋白的表达,减轻癫患儿炎性反应,从而减轻脑损伤,效果优于丙戊酸钠。
Objective To investigate the effects of levetiracetam on serum hs-CRP and S100B in epileptic children. Methods Sixty children with epilepsy were randomly divided into control group (30 cases) and observation group (30 cases). The control group was treated with sodium valproate, while the observation group was treated with levetiracetam. Serum hs-CRP and S100B protein levels were measured before treatment and 6 months after treatment. Results The clinical curative effect in the two groups was compared with the control group, 9 cases in the observation group, 18 cases were markedly effective, 3 cases were ineffective, the total effective rate was 90.0%; 5 cases in control group, 17 cases markedly effective, 8 ineffective, the total effective rate was 73.3%, 2 The difference was statistically significant (P <0.05). The levels of serum hs-CRP and S100B protein in the observation group were (1.38 ± 0.61) mg.L-1 and (0.516 ± 0.204) μg.L-1 respectively, while those in the control group were (2.96 ± 1.42) mg after treatment. L-1 and (0.674 ± 0.216) μg.L-1 and 2 groups decreased compared with those before treatment, and the degree of decrease in the observation group was more obvious than that in the control group (P <0.05). Conclusion Levetiracetam can relieve the brain injury by reducing the expression of hs-CRP and S100B, and relieve the inflammatory reaction in epileptic children, which is superior to sodium valproate.